Ironwood Pharmaceuticals's revenue for the
three
months ended in Dec. 2023 was $117.6 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $442.7 Mil.
Ironwood Pharmaceuticals's Revenue per Share for the
three
months ended in Dec. 2023 was $0.75.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.61.
During the past 12 months, the average Revenue per Share Growth Rate of Ironwood Pharmaceuticals was 29.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 5.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 1.50% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 22.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Ironwood Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 112.10% per year. The lowest was -41.10% per year. And the median was 6.05% per year.
Ironwood Pharmaceuticals Revenue Historical Data
The historical data trend for Ironwood Pharmaceuticals's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Ironwood Pharmaceuticals's Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, Ironwood Pharmaceuticals's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ironwood Pharmaceuticals's Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ironwood Pharmaceuticals's Revenue distribution charts can be found below:
* The bar in red indicates where Ironwood Pharmaceuticals's Revenue falls into.
Ironwood Pharmaceuticals Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $442.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Ironwood Pharmaceuticals Revenue Related Terms
Thank you for viewing the detailed overview of Ironwood Pharmaceuticals's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Ironwood Pharmaceuticals (Ironwood Pharmaceuticals) Business Description
Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IRWD has been successfully added to your 